Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
about
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradationMechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pHThe proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2Self-association of human PCSK9 correlates with its LDLR-degrading activityAnnexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levelsThe PCSK9 decadeNew developments in atherosclerosis: clinical potential of PCSK9 inhibitionHypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease riskProprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesCholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemiaTrafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainThe self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domainMolecular basis for LDL receptor recognition by PCSK9Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 CellsA proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesStructural and functional analysis of the CspB protease required for Clostridium spore germinationStructure of the Mycosin-1 Protease from the Mycobacterial ESX-1 Protein Type VII Secretion SystemIdentification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein ReceptorNew Era of Lipid-Lowering DrugsDynamics of hepatic and intestinal cholesterol and bile acid pathways: The impact of the animal model of estrogen deficiency and exercise trainingPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the futureStructural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptorCatalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cellsIn vivo evidence that furin from hepatocytes inactivates PCSK9The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functionsA proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.Molecular population genetics of PCSK9: a signature of recent positive selection.Fabs enable single particle cryoEM studies of small proteinsNovel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.A cholesterol-lowering VLP vaccine that targets PCSK9The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populationsA two-step binding model of PCSK9 interaction with the low density lipoprotein receptorPeptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management
P2860
Q24294486-89E497C2-2981-4868-8C70-E083A1383273Q24297165-A2A75697-AB31-43DA-A456-7DC41E1E4929Q24301411-12C3AAC9-79F4-4C36-8B16-0C143753A218Q24306591-9517C5BF-570D-490B-8201-B2335DD06A82Q24313575-60591CB2-9F5B-4EF5-9DA4-EC34CDC61AD4Q24615397-E055421A-ED07-43DF-9A88-4E046F640D0DQ26783407-D3A324E9-1638-4061-BA3C-9EC704A10F4BQ26786549-5288F3C0-20A4-4535-983D-63235C25EF4DQ27003094-B43586C4-5BC1-48B3-8D5E-9FAE9E3B0A8CQ27009477-AB3AF395-3B7E-49C7-A7BF-06E5316C7E6AQ27013494-5C12CAC5-908C-489B-8FDB-6464FAA6AF9DQ27339783-AE5996FC-CDFB-4AE0-8647-1B91A7418AABQ27647905-8B9B2C9B-0983-41C3-8689-9605A6DB121BQ27649779-EAACE32E-5114-4875-8C9A-0DD968845208Q27653836-1635DD7B-7F3E-416A-8954-C867C7DD832DQ27655476-7A0D7FE8-63B4-47EC-A752-C11616B69E1BQ27676376-FD960B8B-DA58-4C63-8BB1-0F1003E68BD5Q27677641-4DE86180-130A-491E-982A-793CE196EDB1Q27680601-5C591D0D-5CB4-47F8-8780-D6D956625BF1Q28072298-A71AA1EF-78F3-427A-B524-810CEA83369EQ28073180-591AE763-B115-4937-AAC6-EEBC4857C4BAQ28083595-32500CCC-3D95-40E7-B025-34089D044C54Q28292154-9156AABA-66CF-496F-B15B-C666FA4251FEQ28304381-299F48DB-9DC2-4EA7-95A7-22E77E23854DQ28504537-F7408554-8EB9-43D5-86A5-E75139F4BCA9Q30541820-DB85A8C1-A59B-4896-8047-1B6B20ACC41EQ33532964-AE951F6A-FF8D-4C2A-92EE-2B12CCCE12D4Q33599961-FEC28FFF-8FA6-44DB-BE32-D09C1E384387Q33625574-7CC0D9F7-9189-456C-8DCE-33D0C65BE49CQ33743727-1A393206-D838-4746-880F-B31C7D047379Q34223995-36B81930-920E-43D7-82B2-0C25C1D49E77Q34227474-0CFBC559-E8D1-4DC1-94A0-7155D74DE605Q34355679-3A8C71C4-311E-41D3-A075-5E2D94828491Q34430377-898C47ED-BE0F-45FF-B997-72260E782172Q34433146-CAD44F8B-D71B-4091-AC71-7A6EE6A70283Q34479132-66A668BA-D91C-49A1-8E57-CC23BE6D4210Q34496015-3FD551FD-AAD1-4323-8E72-B0365A598F39Q34559768-D3138001-1C5B-4FA9-90E2-CC770672B451Q34568486-24C7EACF-4E0A-43BC-9069-5668AAD99AC3Q34634698-9331E22F-7B12-48EC-9ADC-4F11441B41F9
P2860
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Structural and biophysical stu ...... familial hypercholesterolemia
@ast
Structural and biophysical stu ...... familial hypercholesterolemia
@en
Structural and biophysical stu ...... familial hypercholesterolemia
@nl
type
label
Structural and biophysical stu ...... familial hypercholesterolemia
@ast
Structural and biophysical stu ...... familial hypercholesterolemia
@en
Structural and biophysical stu ...... familial hypercholesterolemia
@nl
prefLabel
Structural and biophysical stu ...... familial hypercholesterolemia
@ast
Structural and biophysical stu ...... familial hypercholesterolemia
@en
Structural and biophysical stu ...... familial hypercholesterolemia
@nl
P2093
P2860
P3181
P356
P1476
Structural and biophysical stu ...... familial hypercholesterolemia
@en
P2093
Alison H Varghese
Andrew P Seddon
David Cunningham
Dennis E Danley
Donghui Xia
Jeffrey S Culp
Julie L Hawkins
Katherine M McGrath
Kieran F Geoghegan
Kim J Stutzman-Engwall
P2860
P2888
P3181
P356
10.1038/NSMB1235
P577
2007-05-01T00:00:00Z
P5875
P6179
1035856633